SBIR/STTR Research Award
WHICH ISOTYPE OF ECD4-IG MOST EFFECTIVELY SUPPRESSES VIRUS REPLICATION?
Award amount
$1,935,908Program and phase
SBIR · Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- EMMUNE INC
- Proposal award date
- 2017-02-09
- Contract end date
- 2020-01-31
- UEI
- N65ZDYUGWAH8
- Solicitation number
- PA15-269
- Topic code
- r
Research abstract
DESCRIPTIONprovided by applicantWe have engineered a synthetic antibody that neutralizesof HIV strainsThis antibody is built from the parts of CDand CCRthat are recognized by HIVand is named "eCDIg " The goal of our research program is now to maximize its efficacyA fundamental question for our effort and for the field as a whole isWhich isotype of IgG has the properties that are most important for suppressing viral replicationTo answer this questionwe will eliminate problematic features of IgGand IgGthat have historically presented a barrier to their use as therapeutics in humansand we will compare the ability of rhesus IgGIgGand IgGforms of eCDIg to suppress SIV replication in macaquesThe isotype of eCDIg that most completely suppresses viral replication will be advanced to human clinical trials
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Process development for manufacturing eCD4-Ig
- IND-enabling studies for eCD4-Ig as a long-acting recombinant protein therapeutic
- SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
- Process development for manufacturing eCD4-Ig
- SARS-CoV-2 vaccines based on RBDs with engineered glycosylation sites
Research funding history
17 SBIR/STTR records share this UEI (2015–2025). Reported award amounts total $20,456,694. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services